SEC Company Response from Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040) (PHIO) — Feb 7, 2020
Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040)
Date: Feb. 7, 2020 · CIK: 0001533040 · Accession: 0001683168-20-000391
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-234032
Letter
Phio Pharmaceuticals Corp.
257 Simarano Drive, Suite 101
Marlborough, MA 01752
(508) 767-3861
February 7, 2020
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: Joseph McCann
Re: Phio Pharmaceuticals Corp.
Registration Statement on Form S-1
Filed October 1, 2019
File No. 333-234032
Ladies and Gentlemen:
Pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended, Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on Form S-1 filed by the Company (the “Registration Statement”) be accelerated to 9:00 a.m., Eastern Daylight Time, on, February 11, 2020 or as soon thereafter as practicable.
Very truly yours,
Phio Pharmaceuticals Corp.
Show Raw Text
CORRESP
1
filename1.htm
Phio Pharmaceuticals Corp.
257 Simarano Drive, Suite 101
Marlborough, MA 01752
(508) 767-3861
February 7, 2020
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: Joseph McCann
Re: Phio Pharmaceuticals Corp.
Registration Statement on
Form S-1
Filed October 1, 2019
File No. 333-234032
Ladies and Gentlemen:
Pursuant to Rules 460
and 461 promulgated under the Securities Act of 1933, as amended, Phio Pharmaceuticals Corp., a Delaware corporation (the
“Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on
Form S-1 filed by the Company (the “Registration Statement”) be accelerated to 9:00 a.m., Eastern Daylight Time, on,
February 11, 2020 or as soon thereafter as practicable.
Very truly yours,
Phio Pharmaceuticals Corp.
/s/ Gerrit Dispersyn
Gerrit Dispersyn
President and Chief Executive Officer
cc: Ryan A. Murr, Gibson, Dunn & Crutcher LLP